Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company, a research-based global pharmaceutical company, has submitted a new drug application to the Ministry of Health, Labour and Welfare for Actos orally disintegrating tablets 15 and 30, for treatment of type 2 diabetes.
Subscribe to our email newsletter
Takeda is the originator of the thiazolidinedione (TZD) class of oral anti-diabetic medications. Actos is a member of TZDs that help reduce insulin resistance, which is one of the major defects in type 2 diabetes.
Because Actos orally disintegrating (OD) tablets swiftly disintegrate in the oral cavity, they can be taken without water by even aged or other patients who have difficulty in swallowing, the company said.
Masaomi Miyamoto, general manager of pharmaceutical development division at Takeda, said: “The number of patients with type 2 diabetes is increasing among not only the aged but also the middle- and upper-aged population. We will strive to provide Actos OD tablets to the patients with type 2 diabetes as early as possible, thereby further enhancing the diabetes franchise which Takeda has already established.”